Colorado Medicaid's Decision to Cover the Nerivio® REN Wearable Expands Access for Nearly Two Million Americans to Drug-Free, Dual Use Migraine Treatment

News provided by

Jul 10, 2024, 08:30 ET

Colorado Medicaid is the third federally-funded insurance plan to recognize the REN wearable as safe, effective migraine relief for adolescents and adults ages 12 years and older

BRIDGEWATER, N.J. and NETANYA, Israel, July 10, 2024 /PRNewswire/ -- Theranica, a neuromodulation therapeutics company, today announced Health First Colorado - Colorado Medicaid's coverage of the Nerivio^® REN wearable, the FDA-cleared, non-drug, non-disruptive treatment for both acute attacks and prevention of migraine with or without aura in adolescents and adults ages 12 and older. This coverage expands access to 1.7 million members, offering an alternative or supplemental treatment to prescription and over-the-counter medications.

Colorado Medicaid now covers the Nerivio REN wearable, the first FDA-cleared migraine treatment for adolescents and adults ages 12 and older.

Migraine disease is complex and non-curable, affecting 14% of the population, including 100 million adolescents. The majority of prescription medications for treating and preventing migraine are not indicated for adolescents. The Nerivio REN wearable triggers the brain's natural power to address migraine pain and associated symptoms without drugs or disruption, providing a safe, drug-free, and non-disruptive option for underserved patient populations.

Research has shown that early therapeutic intervention may halt or limit migraine progression and disability. There is evidence suggesting that many adults with chronic or refractory migraine developed their migraine as children or adolescents and may not have been treated with adequate therapies in their adolescent years.

"Controlling migraine in general, and especially in adolescents before they transition into adulthood is important to prevent long-term negative consequences and chronification," said Dr. Marius Birlea, a neurologist at the University of Colorado Hospital. "Colorado Medicaid's coverage of the REN wearable addresses a pressing need to change the standard of care for migraine and add a treatment option without drugs. This need is even more critical when considering adolescents who live with migraine, where we have to be twice as careful before putting them on a drug."

Colorado Medicaid serves approximately 25% of Coloradans and this decision continues to build a foundation for commercial insurance providers and other federally-funded programs to follow. Earlier this year, Highmark Inc., Blue Cross Blue Shield North Dakota, and DC Medicaid announced coverage for the Nerivio REN wearable, leading the effort to provide effective, drug-free migraine treatments to their members.

"Colorado Medicaid's decision to cover the Nerivio REN wearable demonstrates their commitment to the well-being of its members, especially the younger ones," said Alon Ironi, CEO of Theranica. "Migraine treatment options for the adolescent age group across the U.S. are limited, leaving many patients with an urgent unmet need to cope with this debilitating neurological disorder. We are thrilled that more Americans, and first and foremost adolescents, will now have access to the REN wearable as a treatment option. We look forward to having the other health insurance organizations in Colorado match this important benefit and update their coverage policies accordingly."

Migraine is the second most common reason for missing work and school in the U.S. In adolescents, the impact of migraine disease can result in severe and consequential gaps in learning, inability to participate socially and contribute to mental health issues.

Dr. Birlea added, "Certain migraine medications, including some that are indicated for adolescents, have systemic side effects. When payers acknowledge and cover migraine treatments that have less side effects that are non-systemic, patients will benefit for the long-term."

Payers can also benefit when their members include a REN wearable as part of their migraine treatment plan. According to a health-economics study, payors may save significant amounts of money by covering the REN wearable to prevent migraine, through a drastic reduction of days of acute migraine medication intake.

For more information about the Nerivio REN wearable and to download a prescription form, please visit Nerivio.com.

About Nerivio
Controlled by a smartphone app and self-administered, the Nerivio REN wearable is a complete migraine care treatment that wraps around the upper arm and uses sub-painful Remote Electrical Neuromodulation (REN) to activate nociceptive nerve fibers in the arm. These fibers send signals that trigger a descending pain management mechanism in the brain called conditioned pain modulation (CPM), which turns off migraine pain and associated symptoms without medication. In simpler terms, the upper arm is stimulated to unleash a natural process in the brain to abort or relieve migraine headaches and other associated symptoms. Each treatment lasts 45 minutes and is applied every other day for prevention or at the start of a migraine attack for acute treatment.

About Theranica
Theranica is a neuromodulation therapeutics company dedicated to creating effective, safe, affordable, low-side-effect therapies for idiopathic pain conditions. The company's award-winning flagship wearable, Nerivio®, is the first FDA-cleared prescribed migraine REN wearable for acute and/or preventive treatment of migraine. Nerivio has been used in more than 650,000 migraine treatments in the US, including by adolescents and veterans. Learn more by visiting our websites, theranica.com and nerivio.com, and following us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
#NoMatterWhat